GLUE (Monte Rosa Therapeutics) Dividends Received


GLUE Monte Rosa Therapeutics Inc GLUE
34 GF Score
Price $23.02
! 5 Warning Signs
View Full Analysis

What is Monte Rosa Therapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

GLUE
34GF Score
Monte Rosa Therapeutics Inc GLUE
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monte Rosa Therapeutics Business Description

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
34GF Score

Get the complete analysis for GLUE

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.02
Price